MedTrace Logo

A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS

NCT02490943 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-03-25

No results posted yet for this study

Summary

Peginterferon-beta-1a (PEG) is an approved treatment for relapsing forms of MS that may cause injection related erythema. This is a randomized controlled cross-over trial of superficial hot and cold modalities to reduce injection site erythema caused by PEG.

Conditions

  • MS (Multiple Sclerosis)
  • Erythema

Interventions

OTHER

Warm Compress Before Injection

Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.

OTHER

Cold Compress After Injection

Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.

Sponsors & Collaborators

  • Evergreen Healthcare

    collaborator OTHER

  • Brown, Theodore R., M.D., MPH

    lead INDIV

Principal Investigators

  • Theodore R Brown, M.D., MPH · Evergreen Health Nueroscience Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2019-01-01
Completion
2019-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02490943 on ClinicalTrials.gov